Clinical safety and outcome of recombinant tissue plasminogen activator in patients with stroke attributable to small artery occlusion

Abstract

Background: Recent observations raised concern that the intravenous recombinant tissue plasminogen activator (rt-PA) may result in damage to stroke patients caused by small artery occlusion (SAO). Thus, we perform a protocol for meta-analysis to investigate the efficacy and safety of intravenous thrombolysis with rt-PA in SAO-patients. Methods: The search-style electronic libraries, including Pubmed, Embase, the Cochrane Library, Web of Science, Wanfang Data, VIP Chinese Journals, and China Biomedical Literature Service System are used for document retrieval in June 2021 with no restrictions on language. The risk of bias in include articles will be assessed using the Cochrane Risk of Bias Tool. We perform the meta-analysis by Stata version 10.0 software and calculated the statistics using the inverse variance statistical method. Binary outcomes are presented as Mantel-Haenszel-style risk ratios with 95% confidence interval. Continuous outcomes are reported as mean differences. Results: The results of the article will be shown in a peer-reviewed journal. Conclusion: Intravenous rt-PA may be effective and safe in SAO-patients.

Current status of acute ischemic stroke management in Iran

“…[ 8 ] Although there is no definitive cure for acute ischemic stroke (AIS), using intravenous recombinant tissue plasminogen activator (IV r-tPA) can have an impressive impact on the management of patients with AIS and greatly reduces the burden of the disease. [ 9 ] Time is the biggest challenge of this treatment method and the success of treatment and resultant patient outcomes depend on timely diagnosis of AIS and early administration of IV r-tPA. [ 10 ] Specifically, IV r-tPA is an effective AIS treatment when administered within 4.5 h of symptom onset[ 11 ] and prehospital or in-hospital delays may lead to the loss of opportunity for optimal use.…”